As of 2026-04-04, the Intrinsic Value of Glenmark Pharmaceuticals Ltd (GLENMARK.NS) is 802.50 INR. This GLENMARK.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 2,091.80 INR, the upside of Glenmark Pharmaceuticals Ltd is -61.60%.
The range of the Intrinsic Value is 663.97 - 1,038.64 INR
Based on its market price of 2,091.80 INR and our intrinsic valuation, Glenmark Pharmaceuticals Ltd (GLENMARK.NS) is overvalued by 61.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 663.97 - 1,038.64 | 802.50 | -61.6% |
| DCF (Growth 10y) | 895.11 - 1,376.56 | 1,074.61 | -48.6% |
| DCF (EBITDA 5y) | 1,467.22 - 1,989.39 | 1,637.86 | -21.7% |
| DCF (EBITDA 10y) | 1,527.41 - 2,166.60 | 1,751.55 | -16.3% |
| Fair Value | 188.71 - 188.71 | 188.71 | -90.98% |
| P/E | 1,031.88 - 1,680.17 | 1,260.79 | -39.7% |
| EV/EBITDA | 1,373.10 - 2,671.17 | 1,983.40 | -5.2% |
| EPV | 431.72 - 511.41 | 471.57 | -77.5% |
| DDM - Stable | 248.35 - 539.06 | 393.71 | -81.2% |
| DDM - Multi | 542.79 - 909.12 | 679.18 | -67.5% |
| Market Cap (mil) | 590,305.94 |
| Beta | 0.09 |
| Outstanding shares (mil) | 282.20 |
| Enterprise Value (mil) | 576,079.30 |
| Market risk premium | 8.31% |
| Cost of Equity | 12.46% |
| Cost of Debt | 8.68% |
| WACC | 12.20% |